echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Cardiovasc diabetol: effect of pheneridone vs GLP-1 RA and SGLT2i on cardiorenal prognosis in DM patients with CKD

    Cardiovasc diabetol: effect of pheneridone vs GLP-1 RA and SGLT2i on cardiorenal prognosis in DM patients with CKD

    • Last Update: 2022-11-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    In recent years, the prevalence of diabetes has continued to rise, with about 536.
    6 million people diagnosed with diabetes
    It is estimated that at least 783.
    2 million adults worldwide will be affected
    by diabetes by 2045.

    The aim of this study was to evaluate the cardiovascular and renal benefits
    of pheneridone, a non-steroidal selective mineralocorticoid receptor antagonist, sodium-glucose cotransporter-2 inhibitor (SGLT2i), and glucagon-like peptide-1 receptor agonist (GLP-1 RA) in patients with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD).

    The researchers systematically searched the PubMed, Cochrane Library, Web of Science, Medline, and Embase websites for randomised controlled trials
    comparing phenilidone, SGLT-2i, and GLP-1 RA treatment in people with diabetes complicated by CKD.
    The effects
    of the two drugs were indirectly compared with pheneridone through a network meta-analysis.

    Risk effects of various drugs compared to MACE

    Eighteen randomised controlled trials with a total of 51,496 patients
    were included.
    Pheneridone reduced the risk of major adverse cardiovascular events (MACE), renal prognosis, and heart failure hospitalization (HHF) (RR 0.
    88, 0.
    86, and 0.
    79, respectively).

    SGLT-2i was associated
    with a reduced risk of MACE (RR 0.
    84), renal prognosis (RR 0.
    67), HHF (RR 0.
    60), all-cause death (ACD, RR 0.
    89), and cardiovascular death (RR 0.
    86) compared with placebo.
    GLP-1 RA was associated with a lower risk of MACE (RR 0.

    SGLT2i has significant benefits in renal prognosis and HHF prognosis compared with phenirenone and GLP-1 RA (phenirenone vs SGLT2i: RR 1.
    29 and 1.
    31; GLP-1 RA vs SGLT2i: RR 1.
    36 and 1.

    Risk effects of various drugs compared to renal prognosis

    In summary, SGLT2i, GLP-1 RA and noneridone were comparable in MACE, ACD, and CVD
    in T2DM patients with CKD.
    SGLT2i significantly reduces the risk of
    renal events and HHF in patients with T2DM with CKD compared with pheninone and GLP-1 RA.

    Original source:

    Zhang, Y.
    , Jiang, L.
    , Wang, J.
    et al.
    Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.
    Cardiovasc Diabetol 21, 232 (2022).

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.